SM
LJPC

Sabby Management’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Sabby Management’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-336
Closed -$589K – 371
2016
Q4 		$589K Buy
+336
New +$6.44K 0.03% 185

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sabby Management's LJPC Position: Q1 2017 in Review

Sabby Management sold out of La Jolla Pharmaceutical Company (LJPC) in Q1 2017, closing a stake of 210,978 shares — an estimated $5.39M sold.

Sabby Management first reported a position in LJPC in Q3 2015 and held it in 6 quarters. The position peaked at $3.7M in Q4 2016. 96 funds tracked by Wall St. Rank hold LJPC as of Q1 2017.

  • Sabby Management reported no remaining La Jolla Pharmaceutical Company position as of Q1 2017 after selling out during the quarter.
  • Sabby Management sold 210,978 La Jolla Pharmaceutical Company shares in Q1 2017, an estimated $5.39M.
  • Sabby Management first reported a position in La Jolla Pharmaceutical Company in Q3 2015 and held it in 6 quarters.
  • Sabby Management's La Jolla Pharmaceutical Company position peaked at $3.7M in Q4 2016.
  • 96 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q1 2017.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.